Tags

Type your tag names separated by a space and hit enter

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Diabetes Obes Metab. 2005 Jul; 7(4):430-8.DO

Abstract

AIM

The metabolic syndrome (MS) increases the risk of coronary heart disease, yet few data are available on the effects of statin treatment in improving lipid measures in patients with the syndrome. This analysis compares the effects of statin therapy on plasma low-density lipoprotein cholesterol (LDL-C) goal achievement and lipid levels in hypercholesterolaemic patients with or without the MS.

METHODS

The Measuring Effective Reductions in Cholesterol Using Rosuvastatin TherapY I (MERCURY I) trial compared rosuvastatin 10 mg with atorvastatin 10 mg and 20 mg, simvastatin 20 mg and pravastatin 40 mg over 8 weeks in patients with coronary or other atherosclerotic diseases or diabetes who had fasting levels of LDL-C of >or=2.99 mmol/l and triglycerides of <4.52 mmol/l. Modified National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria for the MS were met by 1342 (43%) of 3140 patients.

RESULTS

LDL-C goal achievement rates and reductions in LDL-C, total cholesterol and non-high-density lipoprotein cholesterol (HDL-C) were similar in patients with and without the MS within statin treatment groups; triglycerides were reduced more and HDL-C tended to be increased more in patients with the MS, as expected. Treatment with rosuvastatin 10 mg was more effective in allowing patients with and without the MS to reach European and ATP III LDL-C goals, compared to atorvastatin 10 mg, simvastatin 20 mg and pravastatin 40 mg (p < 0.0001 for all comparisons); consistently produced greater reductions in LDL-C, total cholesterol and non-HDL-C, compared to these treatments; and produced similar or greater reductions in triglycerides and increases in HDL-C, compared to the other treatments.

CONCLUSIONS

Statin therapy is effective in allowing LDL-C goal achievement and improving the lipid profile in hypercholesterolaemic high-risk patients with the MS. Rosuvastatin 10 mg presents significant advantages in goal achievement and lipid lowering over other statins at commonly used doses in patients both with and without the MS.

Authors+Show Affiliations

Department of Clinical Biochemistry, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. stst@gentoftehosp.kbhamt.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15955130

Citation

Stender, S, et al. "Comparison of Rosuvastatin With Atorvastatin, Simvastatin and Pravastatin in Achieving Cholesterol Goals and Improving Plasma Lipids in Hypercholesterolaemic Patients With or Without the Metabolic Syndrome in the MERCURY I Trial." Diabetes, Obesity & Metabolism, vol. 7, no. 4, 2005, pp. 430-8.
Stender S, Schuster H, Barter P, et al. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab. 2005;7(4):430-8.
Stender, S., Schuster, H., Barter, P., Watkins, C., & Kallend, D. (2005). Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes, Obesity & Metabolism, 7(4), 430-8.
Stender S, et al. Comparison of Rosuvastatin With Atorvastatin, Simvastatin and Pravastatin in Achieving Cholesterol Goals and Improving Plasma Lipids in Hypercholesterolaemic Patients With or Without the Metabolic Syndrome in the MERCURY I Trial. Diabetes Obes Metab. 2005;7(4):430-8. PubMed PMID: 15955130.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. AU - Stender,S, AU - Schuster,H, AU - Barter,P, AU - Watkins,C, AU - Kallend,D, AU - ,, PY - 2005/6/16/pubmed PY - 2005/12/20/medline PY - 2005/6/16/entrez SP - 430 EP - 8 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 7 IS - 4 N2 - AIM: The metabolic syndrome (MS) increases the risk of coronary heart disease, yet few data are available on the effects of statin treatment in improving lipid measures in patients with the syndrome. This analysis compares the effects of statin therapy on plasma low-density lipoprotein cholesterol (LDL-C) goal achievement and lipid levels in hypercholesterolaemic patients with or without the MS. METHODS: The Measuring Effective Reductions in Cholesterol Using Rosuvastatin TherapY I (MERCURY I) trial compared rosuvastatin 10 mg with atorvastatin 10 mg and 20 mg, simvastatin 20 mg and pravastatin 40 mg over 8 weeks in patients with coronary or other atherosclerotic diseases or diabetes who had fasting levels of LDL-C of >or=2.99 mmol/l and triglycerides of <4.52 mmol/l. Modified National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria for the MS were met by 1342 (43%) of 3140 patients. RESULTS: LDL-C goal achievement rates and reductions in LDL-C, total cholesterol and non-high-density lipoprotein cholesterol (HDL-C) were similar in patients with and without the MS within statin treatment groups; triglycerides were reduced more and HDL-C tended to be increased more in patients with the MS, as expected. Treatment with rosuvastatin 10 mg was more effective in allowing patients with and without the MS to reach European and ATP III LDL-C goals, compared to atorvastatin 10 mg, simvastatin 20 mg and pravastatin 40 mg (p < 0.0001 for all comparisons); consistently produced greater reductions in LDL-C, total cholesterol and non-HDL-C, compared to these treatments; and produced similar or greater reductions in triglycerides and increases in HDL-C, compared to the other treatments. CONCLUSIONS: Statin therapy is effective in allowing LDL-C goal achievement and improving the lipid profile in hypercholesterolaemic high-risk patients with the MS. Rosuvastatin 10 mg presents significant advantages in goal achievement and lipid lowering over other statins at commonly used doses in patients both with and without the MS. SN - 1462-8902 UR - https://www.unboundmedicine.com/medline/citation/15955130/Comparison_of_rosuvastatin_with_atorvastatin_simvastatin_and_pravastatin_in_achieving_cholesterol_goals_and_improving_plasma_lipids_in_hypercholesterolaemic_patients_with_or_without_the_metabolic_syndrome_in_the_MERCURY_I_trial_ L2 - https://doi.org/10.1111/j.1463-1326.2004.00450.x DB - PRIME DP - Unbound Medicine ER -